Objective: Geocoding and characterizing geographic, community, and environmental characteristics of study participants is frequently done in epidemiological studies. However, participant addresses are identifiable protected health information (PHI) and geocoding must be conducted in a Health Insurance Portability and Accountability Act–compliant manner. Our objective was to create a software application for this process that addresses limitations in current approaches. Materials and Methods: We used a containerization platform to create DeGAUSS (Decentralized Geomarker Assessment for Multi-Site Studies), a software application that facilitates reproducible geocoding and geomarker assessment while maintaining the confidentiality of PHI. To validate the software, 215 350 addresses in Hamilton County, Ohio, were geocoded using DeGAUSS, ArcGIS, Google, and SAS and compared to a gold-standard approach. We distributed the DeGAUSS software to sites in an ongoing multisite study (Electronic Medical Records and Genomics, or eMERGE), and individual sites independently geocoded and assigned median census tract–level income and distance to nearest major roadway to their participants’ addresses, removed associated PHI, and returned deidentified data. Results: Within a multisite study, 52 244 study participants’ addresses across 5 sites were geocoded with a median distance to roadway of 10 022m and a median census tract income of $57 266, demonstrating the feasibility of DeGAUSS within a multisite study. Compared to other commonly used geocoding platforms, DeGAUSS had similar geocoding and geomarker assessment accuracies. Conclusion: The open source DeGAUSS software overcomes multiple challenges in the use of address data in multisite studies and also serves as a more general reproducible research tool for geocoding and geomarker assessment.

Rationale: The timing and duration of traffic-related air pollution (TRAP) exposure may be important for childhood wheezing and asthma development. Objectives: We examined the relationship between TRAP exposure and longitudinal wheezing phenotypes and asthma at age 7 years. Methods: Children completed clinical examinations annually from age 1 year through age 4 years and age 7 years. Parental-reported wheezing was assessed at each age, and longitudinal wheezing phenotypes (early-transient, late-onset, persistent) and asthma were defined at age 7 years. Participants’ time-weighted exposure to TRAP, from birth through age 7 years, was estimated using a land-use regression model. The relationship between TRAP exposure and wheezing phenotypes and asthma was examined. Measurements and Main Results: High TRAP exposure at birth was significantly associated with both transient and persistent wheezing phenotypes (adjusted odds ratio [aOR] = 1.64; 95% confidence interval [CI], 1.04–2.57 and aOR = 2.31; 95% CI, 1.28–4.15, respectively); exposure from birth to age 1 year and age 1 to 2 years was also associated with persistent wheeze. Only children with high average TRAP exposure from birth through age 7 years were at significantly increased risk for asthma (aOR = 1.71; 95% CI, 1.01–2.88). Conclusions: Early-life exposure to TRAP is associated with increased risk for persistent wheezing, but only long-term exposure to high levels of TRAP throughout childhood was associated with asthma development.